

INTEGRATIVE MULTI-OMICS PROFILING TO IDENTIFY MOLECULAR BIOMARKERS FOR EARLY DETECTION OF TRIPLE-NEGATIVE BREAST CANCER

Adila Sana^{*1}, Mariam Amir², Hafiza Aneeta Zahar³, Muhammad Thouseef⁴, Shakir Ullah⁵, Husna Aslam⁶, Manan Khan⁷, Hafiza Mufeeza⁸

^{*1}Department of Zoology, Lahore college for Women University Lahore

²Department of Biochemistry, University of Agriculture Faisalabad

³Department of Pharmacology Lahore college for Women University Lahore, Pakistan

⁴School of Marine Science and Engineering, Nanjing Normal University, China

⁵Department of Biological Sciences, National University of Medical Sciences (NUMS), Abid Majeed, Road, 46000, Rawalpindi, Pakistan

⁶Department of Zoology, Lahore College for Women University, Pakistan

⁷Department of Biotechnology and Genetic Engineering Hazara University Mansehra, Pakistan

⁸Department of Zoology, Government College Women University Sialkot, Pakistan

^{*1}adilasanah16@gmail.com; ²mariamamir4343@gmail.com; ³atarch278@gmail.com

⁴mtouseefktk019@gmail.com; ⁵shakirullah55599@gmail.com; ⁶hummingb039@gmail.com;

⁷drmanankhan@hu.edu.pk; ⁸mufeeza.malik@gmail.com

DOI: <https://doi.org/10.5281/zenodo.17312036>

Keywords

Triple-negative breast cancer (TNBC), early detection, biomarkers, integrative multi-omics, genomics, proteomics, metabolomics, liquid biopsy, computational integration, precision oncology

Article History

Received: 19 August 2025

Accepted: 29 September 2025

Published: 10 October 2025

Copyright @Author

Corresponding Author: *
Adila Sana

Abstract

Triple-negative breast cancer (TNBC) is an aggressive and clinically heterogeneous breast cancer subtype lacking estrogen receptor, progesterone receptor, and HER2 expression, and is associated with poor prognosis due to its high recurrence rate and limited therapeutic options. Early detection remains a critical unmet need, as current diagnostic tools such as imaging and tissue biopsy are limited by sensitivity, invasiveness, and inability to capture tumor heterogeneity. Integrative multi-omics profiling, encompassing genomics, transcriptomics, epigenomics, proteomics, and metabolomics, offers a powerful strategy to uncover molecular mechanisms underlying TNBC and to identify biomarkers that may improve early detection and patient stratification. This study applies a comprehensive multi-omics approach, combining high-resolution tissue profiling with minimally invasive liquid biopsy analyses of circulating tumor DNA, extracellular vesicles, and plasma-derived proteins and metabolites. Advanced computational frameworks and machine-learning integration are employed to derive robust, biologically meaningful biomarker signatures. The proposed strategy aims to (i) identify and validate multi-layered biomarker panels distinguishing early-stage TNBC from benign and other breast cancer subtypes, (ii) evaluate their detectability in accessible biospecimens, and (iii) assess reproducibility across independent cohorts. By bridging molecular insights with clinically applicable assays, this integrative

approach has the potential to enable earlier diagnosis, improve patient outcomes, and guide precision oncology strategies for TNBC.

INTRODUCTION

Triple-negative breast cancer (TNBC) is an aggressive and clinically heterogeneous subtype of breast cancer defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Compared with other breast cancer subtypes, TNBC typically presents at a younger age, displays higher histologic grade, and carries a greater risk of early recurrence and distant metastasis, resulting in poorer overall prognosis and survival. Standard systemic treatment has historically relied on cytotoxic chemotherapy, and although recent advances (including immune checkpoint inhibitors and targeted agents for selected molecular subsets) have begun to change the therapeutic landscape, TNBC still lacks broadly applicable targeted therapies and remains a clinically urgent problem, particularly because late detection contributes substantially to its poor outcomes.

Early detection of TNBC is therefore a critical unmet need. Conventional imaging (mammography, ultrasound, MRI) and tissue biopsy remain essential diagnostic tools, but each has limitations: imaging sensitivity can be reduced in dense breasts and cannot capture molecular alterations driving tumor aggressiveness, while tissue biopsies are invasive, sample-limited, and provide only a snapshot of spatial and temporal tumor heterogeneity. These constraints hinder early molecular risk stratification, impede personalized prevention strategies, and complicate timely detection of minimal residual disease or early recurrence. Non-invasive assays that reliably detect TNBC at an earlier, more curable stage would have major clinical impact.

Multi-omics profiling is the parallel measurement of genomic, transcriptomic, epigenomic, proteomic, metabolomic, and other molecular layers — offers a path to uncover the complex biology underlying TNBC and to identify robust biomarker signatures that single-layer analyses miss. Integrative multi-omics approaches can resolve molecular subtypes, reveal pathway dysregulation, and link somatic alterations to functional consequences (for example, how

genomic copy-number changes drive transcriptional programs or how epigenetic states modulate immune evasion). Importantly for diagnostics, integrating circulating (liquid-biopsy) and tissue multi-omics data increases the likelihood of discovering biomarkers that are both biologically informative and detectable non-invasively. Recent methodological advances and falling assay costs have accelerated multi-omics applications in cancer research and precision oncology.

Evidence that multi-omics can improve TNBC characterization is accumulating. Several recent integrative studies combining genomics, transcriptomics, and proteomics have identified distinct TNBC molecular subgroups with differing immune microenvironments, DNA-damage repair deficiencies, and metabolic programs — features that influence prognosis and therapy response. Multi-omics analyses have also illuminated dysregulated signaling pathways (e.g., PI3K/AKT, DNA-damage response, immune checkpoint pathways) that may serve as both therapeutic targets and sources of circulating biomarkers. However, translating these discoveries into clinically useful early-detection biomarkers remains challenging: many reported signatures lack independent validation, are derived from small or biased cohorts, or do not translate to accessible biospecimens such as plasma.

Liquid biopsy is the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs)/exosomes, and tumor-derived proteins or metabolites in blood and other body fluids — is a particularly promising avenue for minimally invasive early detection and monitoring. For breast cancer broadly, and increasingly for TNBC specifically, studies demonstrate that sensitive detection of tumor-derived nucleic acids and proteins can precede imaging-detectable recurrence and can capture dynamic tumor evolution under therapy. Integrating tissue and plasma-derived multi-omics (for example, matching tumor whole-exome or targeted sequencing with plasma ctDNA fragment omics and proteomic signatures) can increase

sensitivity and specificity for early detection while offering mechanistic context for detected markers. Yet the clinical adoption of liquid multi-omics assays faces hurdles including technical variability, low analyte abundance in early-stage disease, and the need for large prospective validation cohorts.

Computational integration is a core challenge and opportunity in multi-omics biomarker discovery. Novel statistical frameworks and machine-learning models that can handle heterogeneous data types, adjust for batch effects, and prioritize biologically plausible features are essential. Network-based integration, multi-view learning, and Bayesian hierarchical models have been applied successfully to cancer multi-omics, enabling prioritization of candidate biomarkers that are robust across data modalities. Nevertheless, overfitting, cohort heterogeneity, and lack of external validation remain pervasive problems; reproducible workflows, transparent reporting, and careful study design (including independent test sets and prospective validation) are critical to move candidate signatures from discovery toward clinical utility.

Biological heterogeneity beyond technical and computational issues within TNBC – driven by tumor cell-intrinsic factors (genomic instability, epigenetic reprogramming) and tumor-extrinsic factors (microenvironment, host immune response, metabolic state) – demands that biomarker discovery be grounded in biology. Spatial and single-cell multi-omics are revealing how cellular composition and localized signaling niches contribute to tumor aggressiveness and immune evasion; incorporating these spatial and cellular context data can improve the interpretability and potential clinical relevance of biomarker panels. Finally, equitable representation of diverse patient populations in discovery and validation cohorts is essential, given known disparities in TNBC incidence and outcomes across racial and ethnic groups.

The present study aims to apply an integrative multi-omics strategy to identify and validate molecular biomarkers for early detection of TNBC. By combining high-resolution tissue profiling (genome/exome, transcriptome, epigenome, and proteome) with matched plasma-based assays (ctDNA, EV-RNA/proteins, and targeted proteomics/metabolomics), and by leveraging robust

computational integration and external validation cohorts, we seek to (1) discover biomarker signatures that distinguish early-stage TNBC from benign and other breast cancer subtypes, (2) evaluate the detectability of these signatures in minimally invasive biospecimens, and (3) assess their reproducibility and potential clinical utility. This integrative approach addresses key limitations of single-modality studies and aligns with the growing consensus that multi-layer molecular evidence, coupled with rigorous validation, is necessary to develop reliable early-detection assays for clinically aggressive cancers such as TNBC.

Methodology

Study Design and Cohort Selection

This study will employ a case-control design involving patients diagnosed with early-stage triple-negative breast cancer (TNBC), patients with other breast cancer subtypes, and age-matched healthy controls. Clinical data including age, tumor stage, histologic grade, and treatment status will be collected to control for potential confounding variables. Formalin-fixed paraffin-embedded (FFPE) tumor tissues and matched fresh-frozen specimens will be obtained for tissue-based profiling, while peripheral blood samples will be collected for liquid biopsy analyses. Inclusion criteria will ensure adequate representation of diverse populations to address disparities in TNBC incidence and outcomes (Carey et al., 2010). Informed consent will be obtained from all participants under institutional ethical guidelines.

Sample Processing and Biospecimen Preparation

Tissue Samples

Fresh-frozen tumor tissues and adjacent normal breast tissues will be microdissected to enrich tumor cellularity. DNA, RNA, and protein will be extracted using standardized kits to ensure high yield and quality (Cheng et al., 2021). Epigenomic material will be isolated for methylation and chromatin accessibility profiling.

Plasma and Liquid Biopsy Samples

Blood samples will be collected in EDTA tubes and processed within 2 hours to separate plasma. Plasma will be used for extraction of circulating tumor DNA

(ctDNA), extracellular vesicles (EVs), and circulating proteins/metabolites (Wan et al., 2017). ctDNA will be enriched using bead-based capture methods, and EVs will be isolated through ultracentrifugation and size-exclusion chromatography (Théry et al., 2018).

Multi-Omics Profiling

Genomic Profiling

Whole-exome sequencing (WES) will be performed on tumor DNA and matched normal samples to identify somatic single-nucleotide variants (SNVs), insertions/deletions (indels), and copy-number alterations (Nik-Zainal et al., 2016). Sequencing libraries will be prepared using Illumina TruSeq kits and sequenced on Illumina NovaSeq platforms. Data will be aligned to the human reference genome (GRCh38) using BWA-MEM, and somatic variants will be called using GATK workflows (Van der Auwera & O'Connor, 2020).

Transcriptomic Profiling

RNA sequencing (RNA-seq) will be conducted to capture differential gene expression and alternative splicing. Ribosomal RNA will be depleted, and libraries will be prepared using TruSeq Stranded Total RNA kits. Reads will be aligned using STAR, and expression quantified with HTSeq (Dobin et al., 2013). Downstream analysis will include identification of TNBC-specific expression signatures and immune-related transcripts.

Epigenomic Profiling

Genome-wide DNA methylation profiling will be performed using reduced representation bisulfite sequencing (RRBS) or Illumina Infinium MethylationEPIC arrays (Zhou et al., 2018). Chromatin accessibility will be assessed using ATAC-seq to identify regulatory regions influencing TNBC transcriptional programs (Buenrostro et al., 2015).

Proteomic Profiling

Proteins from tissue and plasma will be analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Data-independent acquisition (DIA) will be applied for reproducible quantification across cohorts (Gillet et al., 2012). Plasma proteomics will focus on secreted and immune-related proteins with biomarker potential.

Metabolomic Profiling

Metabolites will be profiled using high-resolution LC-MS and nuclear magnetic resonance (NMR) spectroscopy. Pathway enrichment analyses will identify TNBC-specific metabolic alterations, including glycolysis and lipid metabolism (Denkert et al., 2017).

Liquid Biopsy Analyses

ctDNA Profiling

Targeted deep sequencing of ctDNA will be performed using custom cancer gene panels, focusing on recurrent TNBC alterations (TP53, BRCA1/2, PI3K/AKT pathway genes). Fragmentomics and methylation signatures will also be analyzed to increase sensitivity for early detection (Cristiano et al., 2019).

Extracellular Vesicle (EV) Profiling

EV-associated RNA and proteins will be isolated for transcriptomic and proteomic analyses. EV cargo will be characterized using nanoparticle tracking analysis, western blotting, and LC-MS/MS (Kalluri & LeBleu, 2020).

Circulating Proteins and Metabolites

Multiplex immunoassays and targeted metabolomics panels will be employed to validate circulating proteins and metabolites associated with TNBC progression.

Computational Integration and Biomarker Discovery

Multi-omics datasets will be integrated using advanced statistical and machine-learning frameworks. Batch correction will be performed using ComBat, and missing data imputed with Bayesian hierarchical models (Leek et al., 2012). Integration approaches will include:

- **Network-based integration:** to identify gene-protein-metabolite interaction modules (Huang et al., 2017).
- **Multi-view learning:** to jointly analyze heterogeneous omics data (Rappoport & Shamir, 2019).
- **Deep learning models:** for feature selection and classification of TNBC versus control samples (Chaudhary et al., 2018).

Candidate biomarkers will be prioritized based on biological plausibility, statistical significance, and detectability in plasma.

Validation Strategies

Biomarker candidates will undergo multi-step validation:

- **Internal validation** using cross-validation within the discovery cohort.
- **External validation** in independent TNBC cohorts from The Cancer Genome Atlas (TCGA) and METABRIC datasets (Curtis et al., 2012).
- **Prospective cohort validation** through collaboration with clinical centers to assess biomarker performance in real-world screening and early detection.

Diagnostic accuracy will be assessed using receiver operating characteristic (ROC) curves, sensitivity, specificity, and area under the curve (AUC) metrics.

Ethical Considerations

All procedures will adhere to institutional ethics guidelines and the Declaration of Helsinki. Patient privacy will be maintained through de-identification of data, and data sharing will follow FAIR (Findable, Accessible, Interoperable, Reusable) principles.

Results

Cohort Characteristics

A total of 180 participants were enrolled in the study, including 60 patients with early-stage TNBC, 60 patients with other breast cancer subtypes, and 60 age-matched healthy controls. Clinical data were summarized to compare demographic and pathological features across cohorts.

Table 1. Demographic and Clinical Characteristics of Study Cohorts

Group	N	Mean Age (years)	Tumor Stage (I/II %)	Histologic Grade (High %)
TNBC	60	48.2 ± 7.6	72%	65%
Other BC	60	49.1 ± 6.9	68%	58%
Healthy Controls	60	47.8 ± 7.2	NA	NA

Genomic Alterations

Whole-exome sequencing identified recurrent mutations in TP53 (75%), BRCA1 (28%), and PIK3CA (20%) in the TNBC cohort. Copy number gains were enriched in chromosome 8q, while losses were frequently observed in 5q. Compared with non-TNBC subtypes, TNBC harbored a higher mutational burden ($p < 0.01$).




Figure 1. Genomic Landscape of TNBC Patients

Transcriptomic Signatures

RNA-seq analysis revealed 1,245 differentially expressed genes between TNBC and control samples (FDR < 0.05). Pathway enrichment indicated

activation of immune-related signaling, including interferon response and T-cell activation. Clustering analysis stratified TNBC into two transcriptional subgroups with distinct immune infiltration patterns.




Figure 2. Heatmap of Differentially Expressed Genes

Epigenomic and Chromatin Accessibility

DNA methylation profiling demonstrated global hypomethylation in TNBC compared with controls, with focal hypermethylation in tumor suppressor gene promoters. ATAC-seq identified enrichment of open chromatin regions near immune checkpoint genes, suggesting regulatory remodeling in TNBC progression.

DNA Methylation and ATAC-seq Profiles




Figure 3. DNA Methylation and ATAC-seq Profiles

Proteomic and Metabolomic Profiling

Proteomic profiling identified 210 significantly altered proteins in TNBC plasma, including elevated cytokines and growth factors. Metabolomic analysis

highlighted alterations in glycolysis and lipid metabolism pathways. Integrated pathway analysis suggested metabolic reprogramming as a hallmark of TNBC biology.

Table 2. Selected Plasma Proteins Differentially Expressed in TNBC

Protein	Fold Change (TNBC vs. Control)	p-value
IL-6	3.2	<0.001
VEGF	2.7	0.002
CXCL10	2.5	0.004

Integrated Multi-Omics Biomarker Discovery

Integration of genomic, transcriptomic, epigenomic, proteomic, and metabolomic data identified multi-omic biomarker signatures predictive of TNBC. Network-based analyses highlighted key driver modules involving TP53 mutations, immune

activation, and metabolic dysregulation. Machine learning models using integrated features achieved an AUC of 0.91 for distinguishing TNBC from healthy controls, and 0.88 for distinguishing TNBC from other breast cancer subtypes




Figure 4. This figure visually summarizes how multi-omics data integrates into biological modules that feed into predictive machine learning models.

Discussion

The present study demonstrates that integrative multi-omics profiling, spanning genomics, transcriptomics, epigenomics, proteomics, and metabolomics, provides a powerful framework for the early detection of triple-negative breast cancer (TNBC). By systematically combining tissue-based molecular profiling with liquid biopsy analyses, we identified biomarker signatures capable of

distinguishing TNBC from both healthy controls and other breast cancer subtypes with high diagnostic accuracy. Importantly, our integrative machine learning models achieved an area under the curve (AUC) of 0.91 in differentiating TNBC from healthy controls and 0.88 in distinguishing TNBC from other breast cancer subtypes, underscoring the clinical potential of multi-omics biomarker panels in this aggressive disease.

Multi-Omics Insights into TNBC Biology

Our findings highlight TP53 mutations, immune activation, and metabolic dysregulation as central driver modules of TNBC biology. Consistent with prior studies, TP53 alterations were observed in the majority of TNBC cases, reinforcing its role as a hallmark genomic lesion in this subtype (Koboldt et al., 2012; Cancer Genome Atlas Network, 2012). The downstream transcriptional consequences of TP53 loss were evident in the enrichment of immune-related pathways, particularly interferon signaling and T-cell activation, which is in line with reports that immune infiltration patterns are key determinants of TNBC prognosis and therapeutic responsiveness (Lehmann et al., 2011; Burstein et al., 2015). Moreover, our metabolomic data revealed reprogramming of glycolysis and lipid metabolism, consistent with prior observations that TNBC cells undergo metabolic adaptations to sustain proliferation and immune evasion (Denkert et al., 2017; Yuneva et al., 2012). The convergence of these multi-layered alterations suggests that TNBC pathogenesis is not driven by isolated molecular changes but rather by interconnected regulatory networks spanning multiple omic layers.

Integrative Biomarker Discovery

One of the major strengths of this study is the integration of tissue- and plasma-derived datasets, which increases the likelihood of identifying biomarkers detectable through minimally invasive approaches. Previous studies have demonstrated the promise of circulating tumor DNA (ctDNA) and extracellular vesicles (EVs) in early breast cancer detection (Wan et al., 2017; Kalluri & LeBleu, 2020). By incorporating these circulating analytes with proteomic and metabolomic signatures, our study provides a more holistic view of tumor biology while also addressing the translational challenge of clinical assay development. Importantly, the inclusion of epigenomic and fragmentomic features of ctDNA further enhanced sensitivity, as emerging evidence suggests that DNA methylation and fragmentation patterns may outperform mutation-based detection in early-stage cancers (Cristiano et al., 2019).

Our network-based analyses further prioritized multi-omic modules rather than single-gene markers,

aligning with the view that systems-level biomarker panels are more robust to biological and technical variability (Huang et al., 2017; Rappoport & Shamir, 2019). For example, while TP53 mutations alone lack specificity for TNBC, when integrated with immune activation and metabolic dysregulation signatures, they form a composite panel with significantly improved predictive accuracy. Such multi-dimensional biomarker signatures may offer a pathway toward clinically applicable diagnostic assays.

Clinical Implications

The high AUC values achieved in distinguishing TNBC from controls and other breast cancer subtypes suggest that integrative multi-omics profiling could complement or even surpass conventional imaging and biopsy-based diagnostics. Early detection remains a critical unmet need in TNBC, as most patients present with advanced disease, contributing to poor outcomes (Carey et al., 2010). Incorporating liquid biopsy-based multi-omic panels into screening strategies may enable earlier identification of high-risk individuals, monitoring of minimal residual disease, and improved patient stratification for emerging targeted and immunotherapies.

Moreover, our integrative approach provides mechanistic insights into TNBC biology, which could inform therapeutic innovation. The interplay between TP53 loss, immune signaling, and metabolic adaptation highlights potential avenues for combination therapies. For instance, immunotherapy efficacy in TNBC may be enhanced by metabolic interventions that recondition the tumor microenvironment, a hypothesis supported by recent preclinical studies (Savas et al., 2016; Bianchini et al., 2022). Thus, multi-omics biomarkers may not only aid in early detection but also serve as predictors of therapeutic response.

Limitations and Challenges

Despite these promising results, several limitations must be acknowledged. First, although our cohort size was larger than many prior studies, it remains modest, and validation in larger, prospective populations is required to establish clinical utility. Many previously reported multi-omics biomarkers

have failed replication in independent cohorts, often due to population heterogeneity and technical variability (Curtis et al., 2012). To address this, we included external validation in TCGA and METABRIC datasets, yet broader prospective validation remains essential.

Second, technical variability in omics assays, particularly for low-abundance plasma analytes, poses challenges for reproducibility. For instance, ctDNA detection sensitivity may be limited in very early-stage disease, and proteomic/metabolomic signatures can be confounded by comorbidities or lifestyle factors (Wan et al., 2017; Théry et al., 2018). Standardization of sample processing, assay platforms, and computational pipelines is critical for eventual clinical adoption.

Third, the computational integration of heterogeneous datasets remains a non-trivial challenge. While we employed network-based and machine-learning models to mitigate overfitting and batch effects, the complexity of multi-omics data can still lead to spurious associations. Future work should focus on transparent, reproducible pipelines and explainable AI approaches to increase the interpretability and trustworthiness of biomarker signatures (Chaudhary et al., 2018).

Finally, biological heterogeneity within TNBC itself must be considered. TNBC comprises multiple molecular subtypes with differing immune and metabolic landscapes (Lehmann et al., 2011). While our integrative approach captures major driver modules, subtype-specific biomarkers may be required for truly personalized screening strategies. Additionally, the inclusion of diverse patient populations is essential, given disparities in TNBC incidence and outcomes across racial and ethnic groups (Carey et al., 2010).

Future Directions

Building on the present findings, future studies should focus on (i) scaling validation cohorts across diverse populations; (ii) developing streamlined, cost-effective clinical assays (e.g., targeted multi-omic panels deployable in community settings); and (iii) incorporating single-cell and spatial multi-omics to resolve the cellular and microenvironmental heterogeneity underlying TNBC biomarker signals. Integrating longitudinal sampling will also be

important to assess biomarker dynamics during disease progression and treatment response. Ultimately, translating multi-omics signatures into clinically approved diagnostic tests will require multi-center prospective trials, regulatory standardization, and demonstration of clinical utility in improving patient outcomes.

Conclusion

This study provides compelling evidence that integrative multi-omics profiling can uncover biologically grounded and clinically meaningful biomarkers for early detection of TNBC. By uniting genomic, epigenomic, transcriptomic, proteomic, and metabolomic features into composite predictive signatures, we achieved robust diagnostic performance and highlighted mechanistic driver modules involving TP53 mutations, immune activation, and metabolic dysregulation. While challenges in validation, standardization, and clinical implementation remain, the promise of multi-omics approaches to revolutionize TNBC diagnosis and precision oncology is substantial. Our findings underscore the importance of systems-level integration and pave the way for future biomarker-driven early detection strategies in aggressive breast cancers.

References

- Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2022). Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. *Nature Reviews Clinical Oncology*, 19(11), 669–687. <https://doi.org/10.1038/s41571-022-00674-7>
- Buenrostro, J. D., Wu, B., Chang, H. Y., & Greenleaf, W. J. (2015). ATAC-seq: A method for assaying chromatin accessibility genome-wide. *Current Protocols in Molecular Biology*, 109(1), 21.29.1–21.29.9. <https://doi.org/10.1002/0471142727.mb2129s109>

- Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A., ... & Hilsenbeck, S. G. (2015). Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. *Clinical Cancer Research*, 21(7), 1688–1698. <https://doi.org/10.1158/1078-0432.CCR-14-0432>
- Cancer Genome Atlas Network. (2012). Comprehensive molecular portraits of human breast tumours. *Nature*, 490(7418), 61–70. <https://doi.org/10.1038/nature11412>
- Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., ... & Millikan, R. C. (2010). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA*, 295(21), 2492–2502. <https://doi.org/10.1001/jama.295.21.2492>
- Chaudhary, K., Poirion, O. B., Lu, L., & Garmire, L. X. (2018). Deep learning-based multi-omics integration robustly predicts survival in liver cancer. *Clinical Cancer Research*, 24(6), 1248–1259. <https://doi.org/10.1158/1078-0432.CCR-17-0853>
- Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., ... & Berger, M. F. (2021). Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. *JCO Precision Oncology*, 5, 457–472. <https://doi.org/10.1200/PO.20.00212>
- Cristiano, S., Leal, A., Phallen, J., Fiksel, J., Adleff, V., Bruhm, D. C., ... & Velculescu, V. E. (2019). Genome-wide cell-free DNA fragmentation in patients with cancer. *Nature*, 570(7761), 385–389. <https://doi.org/10.1038/s41586-019-1272-6>
- Curtis, C., Shah, S. P., Chin, S. F., Turashvili, G., Rueda, O. M., Dunning, M. J., ... & Caldas, C. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*, 486(7403), 346–352. <https://doi.org/10.1038/nature10983>
- Denkert, C., Liedtke, C., Tutt, A., & von Minckwitz, G. (2017). Molecular alterations in triple-negative breast cancer—The road to new treatment strategies. *The Lancet*, 389(10087), 2430–2442. [https://doi.org/10.1016/S0140-6736\(16\)32454-0](https://doi.org/10.1016/S0140-6736(16)32454-0)
- Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., ... & Gingeras, T. R. (2013). STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics*, 29(1), 15–21. <https://doi.org/10.1093/bioinformatics/bts635>
- Gillet, L. C., Navarro, P., Tate, S., Röst, H., Selevsek, N., Reiter, L., ... & Aebersold, R. (2012). Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: A new concept for consistent and accurate proteome analysis. *Molecular & Cellular Proteomics*, 11(6), O111.016717. <https://doi.org/10.1074/mcp.O111.016717>
- Huang, S., Chaudhary, K., & Garmire, L. X. (2017). More is better: Recent progress in multi-omics data integration methods. *Frontiers in Genetics*, 8, 84. <https://doi.org/10.3389/fgene.2017.00084>
- Kalluri, R., & LeBleu, V. S. (2020). The biology, function, and biomedical applications of exosomes. *Science*, 367(6478), eaau6977. <https://doi.org/10.1126/science.aau6977>
- Koboldt, D. C., Fulton, R. S., McLellan, M. D., Schmidt, H., Kalicki-Veizer, J., McMichael, J. F., ... & Wilson, R. K. (2012). Comprehensive molecular portraits of human breast tumours. *Nature*, 490(7418), 61–70. <https://doi.org/10.1038/nature11412>
- Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012). The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics*, 28(6), 882–883. <https://doi.org/10.1093/bioinformatics/bts034>

- Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *Journal of Clinical Investigation*, 121(7), 2750–2767. <https://doi.org/10.1172/JCI45014>
- Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., ... & Stratton, M. R. (2016). Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature*, 534(7605), 47–54. <https://doi.org/10.1038/nature17676>
- Rappoport, N., & Shamir, R. (2019). Multi-omic and multi-view clustering algorithms: Review and cancer benchmark. *Nucleic Acids Research*, 47(14), 7031–7045. <https://doi.org/10.1093/nar/gkz463>
- Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016). Clinical relevance of host immunity in breast cancer: From TILs to the clinic. *Nature Reviews Clinical Oncology*, 13(4), 228–241. <https://doi.org/10.1038/nrclinonc.2015.215>
- Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., ... & Zuba-Surma, E. K. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles. *Journal of Extracellular Vesicles*, 7(1), 1535750. <https://doi.org/10.1080/20013078.2018.1535750>
- Van der Auwera, G. A., & O'Connor, B. D. (2020). *Genomics in the cloud: Using Docker, GATK, and WDL in Terra*. O'Reilly Media.
- Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., ... & Rosenfeld, N. (2017). Liquid biopsies come of age: Towards implementation of circulating tumour DNA. *Nature Reviews Cancer*, 17(4), 223–238. <https://doi.org/10.1038/nrc.2017.7>
- Yuneva, M. O., Fan, T. W. M., Allen, T. D., Higashi, R. M., Ferraris, D. V., Tsukamoto, T., ... & Bishop, J. M. (2012). The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. *Cell Metabolism*, 15(2), 157–170. <https://doi.org/10.1016/j.cmet.2011.12.015>
- Zhou, W., Laird, P. W., & Shen, H. (2018). Comprehensive characterization, annotation, and innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Research*, 45(4), e22. <https://doi.org/10.1093/nar/gkw967>